Treatment of Liver Metastases in Patients with Neuroendocrine Tumors by Granberg, Dan et al.
Hindawi Publishing Corporation
International Journal of Hepatology
Volume 2012, Article ID 790635, 2 pages
doi:10.1155/2012/790635
Editorial
Treatment of Liver Metastases in Patients with Neuroendocrine
Tumors
DanGranberg,1 Wouter de Herder,2 Dermot O’Toole,3 andLarryKvols4
1Division of Endocrine Oncology, Department of Medical Sciences, Uppsala University, SE-751 85 Uppsala, Sweden
2Erasmus University Medical Center, 3015 CE Rotterdam, The Netherlands
3Department of Gastroenterology and Clinical Medicine, St. James’s Hospital and Trinity College Dublin, Dublin, Ireland
4H. Lee Moﬃtt Cancer Center and Research Institute, Tampa, FL 33612, USA
Correspondence should be addressed to Dan Granberg, dan.granberg@medsci.uu.se
Received 25 December 2011; Accepted 25 December 2011
Copyright © 2012 DanGranbergetal.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Neuroendocrine tumours may originate from the lungs,
thymus, stomach, gastrointestinal tract and endocrine pan-
creas. A majority of the tumours are malignant. Metastases
occur to regional and distal lymph nodes, liver, bones, lungs,
mammary glands, subcutaneous tissue, central nervous
system and adrenal glands. Although most neuroendocrine
tumours are relatively slowly growing, poorly diﬀerentiated
neuroendocrine carcinomas are fast growing neoplasms with
high proliferative activity.
A characteristic feature of many neuroendocrine
tumours is the ability to produce and secrete various
hormones and peptides, leading to endocrine symptoms that
can be very disabling and cause substantial morbidity. Small
bowel carcinoids, for example, produce serotonin giving rise
to the classical carcinoid syndrome with ﬂushing, diarrhea,
right-sided heart disease and asthma. A prerequisite for
the carcinoid syndrome to occur is usually the presence of
liver metastases. Lung carcinoids rarely produce serotonin,
but may instead secrete histamine causing an atypical
carcinoid syndrome with generalized ﬂushing, diarrhea,
periorbital oedema, lacrimation and asthma. They may also
produce adrenocorticotropic hormone or corticotropin-
releasing factor, resulting in an ectopic Cushing’s syndrome.
Endocrine pancreatic tumours may as well secrete various
hormones, such as gastrin, insulin, glucagon, vasoactive
intestinal polypeptide (VIP) or somatostatin, resulting in
the corresponding syndrome.
The treatment of patients with metastatic neuroen-
docrine tumours is based on primary tumour origin,
tumour biology, stage and grade and includes debulking by
surgery, liver embolization with particles, chemoemboliza-
tion, radioembolization, radiofrequency ablation and pep-
tide receptor radionuclide therapy (PRRT) with 90Yttrium-
DOTATOC or 177Lutetium-DOTATATE. Medical treatment
consists of biotherapy with alpha-interferon and somato-
statin analogues, various chemotherapy regimens, angio-
genesis inhibitors, tyrosine kinase inhibitors and mTOR
inhibitors. In this special issue in the International Journal of
Hepatology, focus is on the various speciﬁc treatment possi-
bilities for patients with neuroendocrine tumours metastatic
to the liver. There are two papers describing the role of
surgery in these patients, and one clinical study reporting
theresultsoflivertransplantation.Surgicaldebulkingshould
always be considered, and liver transplantation may in
selected cases be an option. Because of the immunosuppres-
sion, it is however of utmost importance that every eﬀort is
made to exclude remaining tumour outside the liver before
transplantation.
Three papers deals with hepatic arterial embolization,
one of them reviews the role of hepatic arterial emboliza-
tion for debulking of liver metastases. Another paper is
about a clinical study and a review of radioembolization,
which is a promising alternative for this patient group
with possible long-lasting eﬀect and few serious adverse
eﬀects. An important disadvantage (also with particle and
chemoembolization) is that most patients with neuroen-
docrine tumours metastatic to the liver in addition have
spread of the tumour to lymph nodes and/or other distant
organs such as the bones, necessitating systemic therapy.
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PRRT is thus often preferred to radioembolization, which
however may be considered if the patient shows progression
later after PRRT. A randomized clinical trial comparing
the various embolization methods, particle embolization,
chemoembolization and radioembolization, would never-
theless be highly desirable.
Three papers review the possible systemic therapies for
patientswithlivermetastasesfromneuroendocrinetumours.
This year, two new drugs have been approved for treatment
of patients with metastatic endocrine pancreatic tumours,
everolimus and sunitinib. This represents an important
progressinthetherapeuticarsenalforpatientswithneuroen-
docrine tumours. There is however still a need for more new
drugs, and especially for patients with midgut carcinoids, in
whom the therapeutic options are limited after progression.
In addition, there is an urgent need to learn how to use,
combine and sequence the various therapeutic alternatives,
includingchemotherapy,biotherapy,newerdrugsandPRRT.
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